EADV

New major survey presented at the EADV Congress finds 'healthy' suntan myths persist despite warnings about skin cancer and aging

Retrieved on: 
Thursday, September 8, 2022
People, Surge arrester, Awareness, Skin cancer, IPSOS, Journal of the European Academy of Dermatology and Venereology, Congress, Coffee, Cosmetics, Venereology, Dermatology

MILAN, Sept. 8, 2022 /PRNewswire/ -- This is despite decades of awareness campaigns linking too much sun exposure to skin cancer and ageing in many countries.

Key Points: 
  • MILAN, Sept. 8, 2022 /PRNewswire/ -- This is despite decades of awareness campaigns linking too much sun exposure to skin cancer and ageing in many countries.
  • Other myths included believing sun protection was not needed in cloudy weather and that you did not need sunscreen if you already had a tan.
  • "We must drive awareness of the damage to skin cells caused by exposure to the sun, which can lead to photoaging and skin cancer.
  • This is particularly important in Europe where sun protection appears most inadequate compared to other countries" added Prof. Thierry Passeron.

Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds

Retrieved on: 
Tuesday, September 6, 2022
University, Bispebjerg Hospital, Shoulder, Dermatitis, Disease, Skin, Barrier, BABY, TARC, Association, European Academy of Allergy and Clinical Immunology, IT University of Copenhagen, Immune system, Population, Biomarker, Risk, Congress, Life, Journal of the European Academy of Dermatology and Venereology, Pharmaceutical industry, Vaccine, Medical device, Venereology, Dermatology

MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.

Key Points: 
  • MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.
  • The study found a positive association between the level of TARC and the severity of eczema.
  • The strips were analysed for immune biomarkers and babies were followed up for the next 2 years.
  • This provides a window of opportunity to develop targeted trials and prevent cases of eczema from occurring", concluded Dr Anne-Sofie Halling.

Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds

Retrieved on: 
Tuesday, September 6, 2022
University, Bispebjerg Hospital, Shoulder, Dermatitis, Disease, Skin, Barrier, BABY, TARC, Association, European Academy of Allergy and Clinical Immunology, IT University of Copenhagen, Immune system, Population, Biomarker, Risk, Congress, Life, Journal of the European Academy of Dermatology and Venereology, Pharmaceutical industry, Vaccine, Medical device, Venereology, Dermatology

MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.

Key Points: 
  • MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.
  • The study found a positive association between the level of TARC and the severity of eczema.
  • The strips were analysed for immune biomarkers and babies were followed up for the next 2 years.
  • This provides a window of opportunity to develop targeted trials and prevent cases of eczema from occurring", concluded Dr Anne-Sofie Halling.